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Abstract
Objective: The definite causes of obsessive-compul-
sive disorder (OCD) are still unknown. Recently, evi-
dence has been growing that OCD has a specific neuro-
chemical and neuroanatomical basis. The most prevail-
ing biological mechanism of OCD is the serotonin
hypothesis. However, in addition to this main hypothe-
sis suggesting serotonin abnormalities, many
researchers have proposed that dopamine might also
participate in the pathophysiology of OCD. Therefore,
the aim of this study was to investigate the association
between dopamine transporter (DAT1) polymorphisms
and OCD. Methods: 115 OCD patients and 160 normal
controls participated in this study. Genomic DNA was
extracted from their blood, and a comparison of the
genotypes and allele frequencies of the DAT1 polymor-
phism between the OCD group and control group was
made. The genotypes of DAT1 are classified into
10/10-repeats and non-10/10 repeats. Results: In this
case-control study, there were no statistical differences
in the observed genotype distributions or allele fre-
quencies of the DAT1 polymorphism between these
two groups. Moreover, there were no significant differ-
ences in the total Y-BOCS, CGI-OC, GAF or total
HDRS scores between the patients with 10/10-repeat
and non-10/10 repeat genotypes. Conclusion: In con-
clusion, DAT1 polymorphisms do not appear to be
associated with the development of OCD, the severity
of OC or depressive symptoms, or the general func-
tioning
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Introduction
Obsessive-compulsive disorder (OCD) is a relatively
common condition, characterized by persistent,
unwanted thoughts and ritualistic behavior. The causes
of this disorder are still unclear, but there is growing
evidence that OCD has some specific neurochemical
and neuroanatomical bases. Although the mode of
transmission is also unknown, a great deal of evidence
from familial, twin, and segregation studies support the
existence of a genetic component in the etiology of
OCD.1
To date, the most prevailing theory concerning the
mechanism of OCD is the serotonin hypothesis.2
However, about 40 % of OCD patients do not respond
to serotonin reuptake inhibitors (SRIs), and some
patients show no convincing functional abnormality
related to serotonin.3 Furthermore, the functioning of
the serotonin system varies from individual to individ-
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ual and is interrelated with other neurotransmitters or
neuronal circuits.3 Therefore, in addition to the main
hypothesis suggesting serotonin abnormalities, some
authors have proposed that dopamine might also partic-
ipate in the pathophysiology of OCD.4 When high con-
centrations of dopamine-related drugs such as amphet-
amine and bromocriptine were administered in animal
studies, stereotypic behaviors similar to the obsessive
behaviors found in OCD patients were observed.4 The
administration of dopamine receptor inhibiting drugs in
combination with an SRI resulted in a reduction in the
obsessive symptoms in OCD patients who showed
resistance to treatment with an SRI alone.5 There have
also been some reports of the emergence of obsessive-
compulsive (OC) symptoms during treatment with
clozapine, a dopamine receptor D4 (DRD4)
antagonist.6 The above evidence obtained from neu-
roanatomical and pharmacological data suggests that
the dopaminergic neurotransmitter system may also be
implicated in mediating OCD. 
The dopamine transporter (DAT1) is one of the can-
didate genes for various behavioral conditions includ-
ing OCD. DAT1 plays a pivotal role in terminating
dopaminergic neurotransmission.7 However, very few
studies of the association between OCD and DAT1
have been conducted. To our knowledge, only two such
studies have been reported to date and in both cases the
results were negative.8,9
Therefore, the aim of this study was to investigate the
association between OCD and DAT1 polymorphisms. 
Methods and Materials 
Subjects 
One hundred and fifteen unrelated patients with OCD
were recruited from Hallym University Sacred Heart
hospital and Youngdong Severance hospital OCD clin-
ic over a period of 24 months. All of the OCD patients
met the DSM-IV criteria for OCD.10 Those subjects
with concomitant major depression (without psychotic
features) were included in the study only if their OC
symptoms were the most prominent and the onset of
OCD antedated the onset of depression. Subjects were
excluded if they presented with a movement disorder
other than a tic disorder, any psychotic symptoms,
mental retardation, alcohol or other substance abuse
within the last 6 months, or a history of psychosurgery,
encephalitis, or significant head trauma. Of the 115
subjects, 37 were taking medications (mainly SSRIs
and low-dose benzodiazepines) and/or were undergo-
ing exposure/response-prevention behavioral therapy.
None of the remaining 78 patients had received any
treatment for their OCD symptoms, at least within the
previous 6 months.
One hundred and sixty unrelated control individuals
were recruited from among the nurses, students and
volunteers at Hallym University Sacred Heart hospital
and Anyang community mental health center. The con-
trol individuals had no history of anxiety, mood or psy-
chotic disorder. All of the subjects were of Korean
descent based on their native language and reported
descent. The protocol was approved by the ethics com-
mittees of Hallym University Sacred Heart hospital and
Youngdong Severance hospital, and all of the subjects
gave their written, informed consent. The obsessive-
compulsive (OC) symptoms and severity were evaluat-
ed and scored by the Y-BOCS11 and Clinical Global
Impression-OCD (CGI-OCD) scales. The severity of
the depressive symptoms in the OCD patients was
scored by the Hamilton Depression Rating Scale
(HDRS)12. Their global functioning was assessed with
the Global Assessment of Functioning (GAF) scale.10
Genotyping
Peripheral blood was collected and genomic DNA
was extracted by a standard procedure. The DAT1
VNTR is located in the 3’ untranslated region of the
gene, and was genotyped as described by Sano et al.13
Statistical analyses
First, the genotype and allele frequencies of the
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patients and controls were analyzed by x2 statistics.
Second, the comparisons of the total Y-BOCS, CGI-
OCD, GAF and HDRS scores according to the DAT1
polymorphisms were performed using the t-test. 
Results
There were no differences in the age or gender distri-
butions between the OCD and control groups (Table 1).
The number of subjects with non-10/10 repeats was
small. An increased level of DAT1 expression was
reported to be associated with the number of 10-repeats
alleles,14 and the 10-repeats allele was reported to
increase DAT1 gene expression compared with the 7-,
9-, and 11-repeats alleles.15 Therefore, we also classi-
fied the genotype of DAT1 into the 10/10-repeats and
non-10/10-repeats groups. 
There were no statistical differences in the observed
genotype distributions or allele frequencies of the DAT1
polymorphism between these two groups (Table 2). 
There were no significant differences in the total Y-
BOCS, CGI-OC, GAF, or total HDRS scores between
the patients with 10/10-repeats and non-10/10 repeats
genotypes (Table 3). 
Discussion
The present study represents a further investigation
into the role of polymorphisms of the DAT1 genes in
OCD. We did not find any association between DAT1
gene polymorphisms and OCD. 
The DAT1 gene is located in chromosome 5p15.3
and has 40bp VNTR(with 3~11 repeats) on the 3’-
untranslated region.16 There is some possibility that
these VNTR influence the gene expression and the
level of DAT1 protein in the brain.17
To our knowledge, only a few studies have been con-
ducted on the association between DAT1 and OCD.
Frisch et al.8) reported that there was no association
between the DAT1 gene and OCD in a Jewish popula-
tion. Hemmings et al.9 did not find any difference in
the distribution of DAT1 VNTR between the OCD and
control groups either. The results of this and the above
two studies suggest that variations in the DAT1 gene
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TABLE 1. Demographic characteristics of obsessive-compulsive
disorder patients and controls
Age (yr)
Sex 1.13 0.31**
Male
Female
79 (68.7%)
36 (31.3%)
31.81 10.71
100 (62.5%)
60 (37.5%)
32.51 6.70 -0.67 0.51*
* t-test
**x2 test
OCD patients
(N=115)
Controls
(N=160)
t/x2 p
TABLE 2. Genotype frequency of DAT1 gene polymorphism in
obsessive-compulsive disorder patients and controls
Genotype
9/10
10/10
10/11
N=115
6 (5.2%)
105 (91.3%)
4 (3.5%)
N=160
11 (6.9%)
142 (88.7%)
7 (4.4%)
0.48 0.79
Genotype
10/10 
Non-10/10
Allele
9-repeats
10-repeats
11-repeats
105 (91.3%)
10 (8.7%)
6 (2.6%)
220 (95.7%)
4 (1.7%)
142 (88.7%)
18 (11.3%)
11 (3.4%)
302 (94.3%)
7 (2.2%)
0.48 0.65
0.46 0.80
x2 test
OCD patients Controls x2 p
TABLE 3. Comparisons of obsessive-compulsive, depressive
symptoms and global function between obsessive-compulsive dis-
order patients with 10/10 and non-10/10 genotype of DAT1 poly-
morphism
Total Y-BOCS
CGI-OC
HDRS
GAF
27.21 5.69
5.37 1.20
13.57 9.36
53.84 9.46
28.17 6.74
5.33 1.03
17.33 8.55
54.17 8.04
0.39
-0.07
0.95
0.08
0.70
0.95
0.34
0.94
Student t-test
10/10 genotype
N=105
Factor score
Non-10/10
genotype
N=10
t p
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are not involved in the pathogenesis of OCD. 
However, in the interpretation of this result, we
should keep in mind the following considerations.
First, the statistical power of the present study may be
compromised by the relatively small sample size.
Therefore, only genes that have a major to moderate
effect on the pathogenesis of OCD are susceptible to be
identified in this study, and the existence of minor
effects of DAT1 VNTR polymorphisms cannot be
excluded. Second, a major obstacle to identifying
genes that have minor effects on the pathogenesis of
OCD is the heterogeneity. Therefore, different genes
might play a role in the pathogenesis of OCD in differ-
ent subgroups of patients. Third, it is also speculated
that multiple genes may operate in unison with one
another, such that the synergic effect of a particular
combination of alleles on the vulnerability to OCD
might be much stronger than that of the individual
genes18. Therefore, studies which attempt to identify a
single candidate gene in isolation may lack statistical
power and reproducibility.9
We could not find any differences in the total Y-
BOCS, CGI-OCD, HDRS or GAF scores between the
patients with 10/10-repeats and non-10/10-repeats.
This suggests that DAT1 VNTR polymorphisms have
no effect on the severity of OCD, depressive symptoms
or general functioning. However, these clinical vari-
ables represent state factors rather than traits, and some
of our OCD patients previously underwent some kind
of treatment. Therefore, caution should be exercised in
interpreting our results and, in order to confirm their
importance, independent replications utilizing a larger
number of drug-naive samples are warranted. 
We do not know the exact causes of the inconsistent
results obtained in this and previous studies of the
DAT1 gene and OCD. Although there is preliminary
evidence which suggests that the DAT1 VNTR poly-
morphism affects the translation of the DAT1 pro-
tein19), the results have varied between studies. Some
researchers found higher DAT1 gene expression in the
10-repeats allele than in the 7-, 9-, and 11-repeats alle-
les.15 whereas others reported that the gene expression
is higher in the 9-repeats allele than in the 10-repeats
allele.17 Martinez et al.20 reported that the VNTR poly-
morphism of the DAT1 gene is not significantly associ-
ated with changes in the DAT1 phenotype in humans.
Furthermore, Jonsson et al.21 did not find any associa-
tion between DAT1 polymorphisms and a major
dopamine metabolite, homovanillic acid, in the cere-
brospinal fluid. It appears that the distribution of the
DAT1 VNTR polymorphism is associated with ethnici-
ty.22 The frequency of the 10-repeats allele in this study
is similar to those reported in other Korean popula-
tions.23,24,25 The frequency of the 10-repeats allele is
higher in Asian populations (as in the present study;
0.86~0.94) than in Caucasian and Black populations
(0.59~0.79). These two factors may at least partially
explain the inconsistencies in the results of previous
studies. 
Although OCD was not included, there have been
several Korean studies of the association between
DAT1 VNTR and ADHD or other psychiatric disor-
ders. Kim et al. reported that the frequencies of the 9-
repeat allele and 9/10 genotype were significantly
higher in the ADHD probands and parents of probands
than in those of the normal control group. They also
suggested the possibility of there being an association
between the DAT1 9-repeat allele and the impulsivity
phenotype of attention deficit and hyperactivity disor-
der (ADHD).24 Shin et al.23 also reported that those
patients with ADHD were more likely to have the 9/10
genotype and 9-repeat allele than the control group.
However, Kim et al.26 did not find any association
between DAT1 and ADHD. Among the various anxiety
disorders, Oh et al.27 reported that there was no associa-
tion between DAT1 VNTR and social phobia. Kim et
al.28 did not find any association between DAT1 VNTR
and depression. 
In conclusion, we found no association between the
DAT1 VNTR polymorphism and OCD. However, it
would be premature to rule out the existence of any
association between DAT1 and OCD and a more defi-
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nite conclusion requires the elucidation of the effects of
allelic variations on DAT1 on DAT1 function or
expression. 
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